Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

ClpP agonist

DRUG CLASS:

ClpP agonist

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

H3.3K27M	Glioma	H3.3K27M	Glioma	ONC201 Sensitive: B - Late Trials ONC201 Sensitive : B	ONC201 Sensitive: B - Late Trials ONC201 Sensitive : B
H3.3K27M	Glioma	H3.3K27M	Glioma	bevacizumab + ONC201 Sensitive: C3 – Early Trials bevacizumab + ONC201 Sensitive : C3	bevacizumab + ONC201 Sensitive: C3 – Early Trials bevacizumab + ONC201 Sensitive : C3
TP53 deletion	Chronic Lymphocytic Leukemia	TP53 deletion	Chronic Lymphocytic Leukemia	ONC212 Sensitive: D – Preclinical ONC212 Sensitive : D	ONC212 Sensitive: D – Preclinical ONC212 Sensitive : D
EGFR overexpression	Glioblastoma	EGFR overexpression	Glioblastoma	ONC201 Resistant: D – Preclinical ONC201 Resistant : D	ONC201 Resistant: D – Preclinical ONC201 Resistant : D
AR splice variant 7	Prostate Cancer	AR splice variant 7	Prostate Cancer	darolutamide + ONC201 Resistant: D – Preclinical darolutamide + ONC201 Resistant : D	darolutamide + ONC201 Resistant: D – Preclinical darolutamide + ONC201 Resistant : D
KRAS G12D	Pancreatic Cancer	KRAS G12D	Pancreatic Cancer	ONC201 Sensitive: D – Preclinical ONC201 Sensitive : D	ONC201 Sensitive: D – Preclinical ONC201 Sensitive : D